EUDA Health Holdings Ltd（EUDA）资讯与事件EUDAEUDA Health Holdings Ltd

EUDA Health Signs MOU with GO POSB to Advance Cell Therapy

EUDA Health provided additional details of the integrated cell therapy program to be pursued under its non-binding Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology, or SIIT. Subject to the execution of definitive agreements and applicable regulatory approvals, parties plan to combine GO POSB's proprietary induced pluripotent stem cell platform and clinical-grade universal tumor organoid bank with SIIT's Natural Killer and NK-TCR cell engineering capabilities and GMP manufacturing expertise to explore for the future development, manufacturing and commercialization of a new generation of off-the-shelf cell therapies for both wellness and oncology applications. EUDA intends to bring together GO POSB and SIIT, fund the joint collaboration, facilitate the commercialization of the contemplated technologies and support global market access. GO POSB intends to provide access to its proprietary iPSC platform, including its clinical-grade universal tumor organoid bank, and support commercialization activities relating to the contemplated technologies. SIIT intends to provide access to its NK and NK-TCR cell engineering capabilities, including directed differentiation of iPSCs into NK cells, genetic engineering, functional maturation, GMP-compliant manufacturing and pre-release testing at its Shenzhen facility.

EUDA Health Signs Tripartite MOU with GO POSB for Next-Gen Therapies

EUDA Health Holdings announced that it has signed a Memorandum of Understanding with GO POSB Organoids Pte and Shenzhen Innovation Immunotechnology Co., Ltd. to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells. The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization of a first of its kind next generation of off-the-shelf oncology cell therapies for cancer treatment applications and wellness Alfred Lim, Chief Executive officer of EUDA commented: "This collaborative agreement represents a significant milestone for our company. The agreement aligns with our strategy to strengthen commercialization and distribution capabilities in innovative, science-backed wellness and non-invasive healthcare products and services. We anticipate the market will be robust for our next generation therapies as we demonstrate the effectiveness of our top of the line suite of product offerings. Our products represent a dramatic improvement over the current products available today. We intend to reach our goal of increasing value for shareholders as we successfully launch this product in the market".

EUDA Health Holdings Ltd Trading Halted Due to Volatility

EUDA Health Holdings Ltd trading halted, volatility trading pause